Global Humanized Mouse Model Market

1 INTRODUCTION OF GLOBAL HUMANIZED MOUSE MODELMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HUMANIZED MOUSE MODELMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY END USER
5.1 Pharmaceutical and Biotechnology Companies
5.2 Contract Research Organizations
5.3 Academic and Research Institutions

6 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY TYPE
6.1 Genetic Humanized Mouse Model
6.2 Cell-Based Humanized Mouse Model
6.2.1 CD34 Humanized Mouse Model (Hu-CD34)
6.2.2 PBMC Humanized Mouse Model
6.2.3 BLT Humanized Mouse Model

7 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY APPLICATION
7.1 Oncology
7.2 Immunology and infectious diseases
7.3 Neurosciences
7.4 Toxicology
7.5 Hematopoiesis
7.6 Others

8 GLOBAL HUMANIZED MOUSE MODELMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL HUMANIZED MOUSE MODELMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 The Jackson Laboratory
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Taconic Biosciences, Inc.
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Horizon Discovery Group PLC
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Genoway S.A.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Humurine Technologies
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Vitalstar Biotechnology Co., Ltd.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Ingenious Targeting Laboratory
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Axenis S.A.S
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Trans Genic, Inc.
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Champions Oncology, Inc.
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments

10.12 Crown Bioscience, Inc.
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Developments

11 Appendix
11.1 Related Reports